Savaysa, Lixiana, Roteas (edoxaban) is a small molecule pharmaceutical. Edoxaban was first approved as Savaysa on 2015-01-08. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat stroke and venous thromboembolism. The pharmaceutical is active against coagulation factor X. Savaysa's patent is valid until 2028-03-28 (FDA).
|Trade Name||Lixiana, Roteas|
|Indication||pulmonary embolism, stroke, venous thromboembolism, venous thrombosis|
|Drug Class||Antithrombotic: blood coagulation factor XA inhibitors|